APO Research
Talk to an analyst

APO RESEARCH · REPORT

Selective Immunosuppressants

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Selective Immunosuppressants Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025190 pages

Choose your research edition.

Industry ResearchSelective Immunosuppressants Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Selective Immunosuppressants Industry Growth and Trends Forecast to 2032125 pages · $3,450 USDMarket StructureGlobal Selective Immunosuppressants Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Selective Immunosuppressants Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal Selective Immunosuppressants Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global Selective Immunosuppressants market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Selective Immunosuppressants is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Selective Immunosuppressants is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Selective Immunosuppressants is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Selective Immunosuppressants is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Selective Immunosuppressants include Chongqing Laimi Pharmaceutical Co., Ltd., Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd., Zhejiang Hisun Pharmaceutical Co., Ltd., Suzhou Changzheng-Xinkai Pharmaceutical Co., Ltd., Shijiazhuang Huaxin Pharmaceutical Co., Ltd., Xiamen Lizhuo Pharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd., Merro Pharmaceutical Co., Ltd. and Jiangsu Yabang Epson Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Selective Immunosuppressants market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Selective Immunosuppressants and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Selective Immunosuppressants sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Selective Immunosuppressants market size, projected growth trends, production technologies, key applications, and end-use industries.

Selective Immunosuppressants Segment by Company

Chongqing Laimi Pharmaceutical Co., Ltd.

Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd.

Zhejiang Hisun Pharmaceutical Co., Ltd.

Suzhou Changzheng-Xinkai Pharmaceutical Co., Ltd.

Shijiazhuang Huaxin Pharmaceutical Co., Ltd.

Xiamen Lizhuo Pharmaceutical Co., Ltd.

Qilu Pharmaceutical Co., Ltd.

Merro Pharmaceutical Co., Ltd.

Jiangsu Yabang Epson Pharmaceutical Co., Ltd.

Jichuang Pharmaceutical Group Co., Ltd.

North China Pharmaceutical Co., Ltd.

Hunan Warner Pharmaceutical Co., Ltd.

Hubei Tianyi Pharmaceutical Co., Ltd.

Fujian Huitian Biopharmaceutical Co., Ltd.

Chenxin Pharmaceutical Co., Ltd.

Changzhou Watson Pharmaceutical Co., Ltd.

Beijing Shuanglu Pharmaceutical Co., Ltd.

Teva

Sanofi

Pfizer

Manus Aktteva Biopharma LLP

Lupin Pharmaceuticals, Inc.

Glenmark Pharmaceuticals US

Alexion Pharmaceuticals, Inc

Selective Immunosuppressants Segment by Type

Leflunomide

Mycophenolate Mofetil

Mycophenolate Sodium

Teriflunomide Tablets

Tofacitinib

Sirolimus

Other

Selective Immunosuppressants Segment by Application

Hospital

Clinic

Other

Selective Immunosuppressants Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Selective Immunosuppressants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Selective Immunosuppressants and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Selective Immunosuppressants.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Selective Immunosuppressants market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Selective Immunosuppressants manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Selective Immunosuppressants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Selective Immunosuppressants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Selective Immunosuppressants Industry Trends Table 2. Selective Immunosuppressants Industry Drivers Table 3. Selective Immunosuppressants Industry Opportunities and Challenges Table 4. Selective Immunosuppressants Industry Restraints Table 5. Global Selective Immunosuppressants Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Selective Immunosuppressants Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Selective Immunosuppressants Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Selective Immunosuppressants Sales Market Share by Manufacturers Table 9. Global Selective Immunosuppressants Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Selective Immunosuppressants Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Selective Immunosuppressants Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Selective Immunosuppressants Manufacturers, Product Type & Application Table 13. Global Selective Immunosuppressants Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Selective Immunosuppressants by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Leflunomide Table 17. Major Manufacturers of Mycophenolate Mofetil Table 18. Major Manufacturers of Mycophenolate Sodium Table 19. Major Manufacturers of Teriflunomide Tablets Table 20. Major Manufacturers of Tofacitinib Table 21. Major Manufacturers of Sirolimus Table 22. Major Manufacturers of Other Table 23. Global Selective Immunosuppressants Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Selective Immunosuppressants Sales by Type (2021-2026) & (K Units) Table 25. Global Selective Immunosuppressants Sales by Type (2027-2032) & (K Units) Table 26. Global Selective Immunosuppressants Sales Market Share by Type (2021-2026) Table 27. Global Selective Immunosuppressants Sales Market Share by Type (2027-2032) Table 28. Global Selective Immunosuppressants Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 29. Global Selective Immunosuppressants Revenue by Type (2021-2026) & (K Units) Table 30. Global Selective Immunosuppressants Revenue by Type (2027-2032) & (K Units) Table 31. Global Selective Immunosuppressants Revenue Market Share by Type (2021-2026) Table 32. Global Selective Immunosuppressants Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Hospital Table 34. Major Manufacturers of Clinic Table 35. Major Manufacturers of Other Table 36. Global Selective Immunosuppressants Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Selective Immunosuppressants Sales by Application (2021-2026) & (K Units) Table 38. Global Selective Immunosuppressants Sales by Application (2027-2032) & (K Units) Table 39. Global Selective Immunosuppressants Sales Market Share by Application (2021-2026) Table 40. Global Selective Immunosuppressants Sales Market Share by Application (2027-2032) Table 41. Global Selective Immunosuppressants Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Selective Immunosuppressants Revenue by Application (2021-2026) & (K Units) Table 43. Global Selective Immunosuppressants Revenue by Application (2027-2032) & (K Units) Table 44. Global Selective Immunosuppressants Revenue Market Share by Application (2021-2026) Table 45. Global Selective Immunosuppressants Revenue Market Share by Application (2027-2032) Table 46. Global Selective Immunosuppressants Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Selective Immunosuppressants Sales by Region (2021-2026) & (K Units) Table 48. Global Selective Immunosuppressants Sales Market Share by Region (2021-2026) Table 49. Global Selective Immunosuppressants Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Selective Immunosuppressants Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Selective Immunosuppressants Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Selective Immunosuppressants Sales by Country (2021-2026) & (K Units) Table 53. North America Selective Immunosuppressants Sales by Country (2027-2032) & (K Units) Table 54. Europe Selective Immunosuppressants Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Selective Immunosuppressants Sales by Country (2021-2026) & (K Units) Table 56. Europe Selective Immunosuppressants Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Selective Immunosuppressants Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Selective Immunosuppressants Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Selective Immunosuppressants Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Selective Immunosuppressants Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Selective Immunosuppressants Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Selective Immunosuppressants Sales by Country (2027-2032) & (K Units) Table 63. Global Selective Immunosuppressants Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Selective Immunosuppressants Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Selective Immunosuppressants Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Selective Immunosuppressants Revenue Market Share by Region (2021-2026) Table 67. Global Selective Immunosuppressants Revenue Market Share by Region (2027-2032) Table 68. Chongqing Laimi Pharmaceutical Co., Ltd. Company Information Table 69. Chongqing Laimi Pharmaceutical Co., Ltd. Business Overview Table 70. Chongqing Laimi Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Chongqing Laimi Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio Table 72. Chongqing Laimi Pharmaceutical Co., Ltd. Recent Development Table 73. Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd. Company Information Table 74. Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd. Business Overview Table 75. Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio Table 77. Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd. Recent Development Table 78. Zhejiang Hisun Pharmaceutical Co., Ltd. Company Information Table 79. Zhejiang Hisun Pharmaceutical Co., Ltd. Business Overview Table 80. Zhejiang Hisun Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Zhejiang Hisun Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio Table 82. Zhejiang Hisun Pharmaceutical Co., Ltd. Recent Development Table 83. Suzhou Changzheng-Xinkai Pharmaceutical Co., Ltd. Company Information Table 84. Suzhou Changzheng-Xinkai Pharmaceutical Co., Ltd. Business Overview Table 85. Suzhou Changzheng-Xinkai Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Suzhou Changzheng-Xinkai Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio Table 87. Suzhou Changzheng-Xinkai Pharmaceutical Co., Ltd. Recent Development Table 88. Shijiazhuang Huaxin Pharmaceutical Co., Ltd. Company Information Table 89. Shijiazhuang Huaxin Pharmaceutical Co., Ltd. Business Overview Table 90. Shijiazhuang Huaxin Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Shijiazhuang Huaxin Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio Table 92. Shijiazhuang Huaxin Pharmaceutical Co., Ltd. Recent Development Table 93. Xiamen Lizhuo Pharmaceutical Co., Ltd. Company Information Table 94. Xiamen Lizhuo Pharmaceutical Co., Ltd. Business Overview Table 95. Xiamen Lizhuo Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Xiamen Lizhuo Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio Table 97. Xiamen Lizhuo Pharmaceutical Co., Ltd. Recent Development Table 98. Qilu Pharmaceutical Co., Ltd. Company Information Table 99. Qilu Pharmaceutical Co., Ltd. Business Overview Table 100. Qilu Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Qilu Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio Table 102. Qilu Pharmaceutical Co., Ltd. Recent Development Table 103. Merro Pharmaceutical Co., Ltd. Company Information Table 104. Merro Pharmaceutical Co., Ltd. Business Overview Table 105. Merro Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Merro Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio Table 107. Merro Pharmaceutical Co., Ltd. Recent Development Table 108. Jiangsu Yabang Epson Pharmaceutical Co., Ltd. Company Information Table 109. Jiangsu Yabang Epson Pharmaceutical Co., Ltd. Business Overview Table 110. Jiangsu Yabang Epson Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Jiangsu Yabang Epson Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio Table 112. Jiangsu Yabang Epson Pharmaceutical Co., Ltd. Recent Development Table 113. Jichuang Pharmaceutical Group Co., Ltd. Company Information Table 114. Jichuang Pharmaceutical Group Co., Ltd. Business Overview Table 115. Jichuang Pharmaceutical Group Co., Ltd. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Jichuang Pharmaceutical Group Co., Ltd. Selective Immunosuppressants Product Portfolio Table 117. Jichuang Pharmaceutical Group Co., Ltd. Recent Development Table 118. North China Pharmaceutical Co., Ltd. Company Information Table 119. North China Pharmaceutical Co., Ltd. Business Overview Table 120. North China Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. North China Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio Table 122. North China Pharmaceutical Co., Ltd. Recent Development Table 123. Hunan Warner Pharmaceutical Co., Ltd. Company Information Table 124. Hunan Warner Pharmaceutical Co., Ltd. Business Overview Table 125. Hunan Warner Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Hunan Warner Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio Table 127. Hunan Warner Pharmaceutical Co., Ltd. Recent Development Table 128. Hubei Tianyi Pharmaceutical Co., Ltd. Company Information Table 129. Hubei Tianyi Pharmaceutical Co., Ltd. Business Overview Table 130. Hubei Tianyi Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Hubei Tianyi Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio Table 132. Hubei Tianyi Pharmaceutical Co., Ltd. Recent Development Table 133. Fujian Huitian Biopharmaceutical Co., Ltd. Company Information Table 134. Fujian Huitian Biopharmaceutical Co., Ltd. Business Overview Table 135. Fujian Huitian Biopharmaceutical Co., Ltd. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Fujian Huitian Biopharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio Table 137. Fujian Huitian Biopharmaceutical Co., Ltd. Recent Development Table 138. Chenxin Pharmaceutical Co., Ltd. Company Information Table 139. Chenxin Pharmaceutical Co., Ltd. Business Overview Table 140. Chenxin Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Chenxin Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio Table 142. Chenxin Pharmaceutical Co., Ltd. Recent Development Table 143. Changzhou Watson Pharmaceutical Co., Ltd. Company Information Table 144. Changzhou Watson Pharmaceutical Co., Ltd. Business Overview Table 145. Changzhou Watson Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Changzhou Watson Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio Table 147. Changzhou Watson Pharmaceutical Co., Ltd. Recent Development Table 148. Beijing Shuanglu Pharmaceutical Co., Ltd. Company Information Table 149. Beijing Shuanglu Pharmaceutical Co., Ltd. Business Overview Table 150. Beijing Shuanglu Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Beijing Shuanglu Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio Table 152. Beijing Shuanglu Pharmaceutical Co., Ltd. Recent Development Table 153. Teva Company Information Table 154. Teva Business Overview Table 155. Teva Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 156. Teva Selective Immunosuppressants Product Portfolio Table 157. Teva Recent Development Table 158. Sanofi Company Information Table 159. Sanofi Business Overview Table 160. Sanofi Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 161. Sanofi Selective Immunosuppressants Product Portfolio Table 162. Sanofi Recent Development Table 163. Pfizer Company Information Table 164. Pfizer Business Overview Table 165. Pfizer Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 166. Pfizer Selective Immunosuppressants Product Portfolio Table 167. Pfizer Recent Development Table 168. Manus Aktteva Biopharma LLP Company Information Table 169. Manus Aktteva Biopharma LLP Business Overview Table 170. Manus Aktteva Biopharma LLP Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 171. Manus Aktteva Biopharma LLP Selective Immunosuppressants Product Portfolio Table 172. Manus Aktteva Biopharma LLP Recent Development Table 173. Lupin Pharmaceuticals, Inc. Company Information Table 174. Lupin Pharmaceuticals, Inc. Business Overview Table 175. Lupin Pharmaceuticals, Inc. Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 176. Lupin Pharmaceuticals, Inc. Selective Immunosuppressants Product Portfolio Table 177. Lupin Pharmaceuticals, Inc. Recent Development Table 178. Glenmark Pharmaceuticals US Company Information Table 179. Glenmark Pharmaceuticals US Business Overview Table 180. Glenmark Pharmaceuticals US Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 181. Glenmark Pharmaceuticals US Selective Immunosuppressants Product Portfolio Table 182. Glenmark Pharmaceuticals US Recent Development Table 183. Alexion Pharmaceuticals, Inc Company Information Table 184. Alexion Pharmaceuticals, Inc Business Overview Table 185. Alexion Pharmaceuticals, Inc Selective Immunosuppressants Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 186. Alexion Pharmaceuticals, Inc Selective Immunosuppressants Product Portfolio Table 187. Alexion Pharmaceuticals, Inc Recent Development Table 188. Key Raw Materials Table 189. Raw Materials Key Suppliers Table 190. Selective Immunosuppressants Distributors List Table 191. Selective Immunosuppressants Customers List Table 192. Research Programs/Design for This Report Table 193. Authors List of This Report Table 194. Secondary Sources Table 195. Primary Sources List of Figures Figure 1. Selective Immunosuppressants Product Image Figure 2. Global Selective Immunosuppressants Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Selective Immunosuppressants Market Size (2021-2032) & (US$ Million) Figure 4. Global Selective Immunosuppressants Sales (2021-2032) & (K Units) Figure 5. Global Selective Immunosuppressants Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Selective Immunosuppressants Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Leflunomide Image Figure 9. Mycophenolate Mofetil Image Figure 10. Mycophenolate Sodium Image Figure 11. Teriflunomide Tablets Image Figure 12. Tofacitinib Image Figure 13. Sirolimus Image Figure 14. Other Image Figure 15. Global Selective Immunosuppressants Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Selective Immunosuppressants Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global Selective Immunosuppressants Sales Market Share by Type (2021-2032) Figure 18. Global Selective Immunosuppressants Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Selective Immunosuppressants Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Selective Immunosuppressants Revenue Market Share by Type (2021-2032) Figure 21. Hospital Image Figure 22. Clinic Image Figure 23. Other Image Figure 24. Global Selective Immunosuppressants Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Selective Immunosuppressants Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Selective Immunosuppressants Sales Market Share by Application (2021-2032) Figure 27. Global Selective Immunosuppressants Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Selective Immunosuppressants Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Selective Immunosuppressants Revenue Market Share by Application (2021-2032) Figure 30. North America Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Selective Immunosuppressants Sales Market Share by Country (2021-2032) Figure 32. U.S. Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Selective Immunosuppressants Sales Market Share by Country (2021-2032) Figure 37. Germany Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Selective Immunosuppressants Sales Market Share by Country (2021-2032) Figure 44. China Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Selective Immunosuppressants Sales Market Share by Country (2021-2032) Figure 52. Brazil Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Selective Immunosuppressants Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Selective Immunosuppressants Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Selective Immunosuppressants Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Selective Immunosuppressants Revenue (2021-2032) & (US$ Million) Figure 63. North America Selective Immunosuppressants Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Selective Immunosuppressants Revenue (2021-2032) & (US$ Million) Figure 65. Europe Selective Immunosuppressants Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Selective Immunosuppressants Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Selective Immunosuppressants Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Selective Immunosuppressants Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Selective Immunosuppressants Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Selective Immunosuppressants Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Selective Immunosuppressants Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Leflunomide
  • Mycophenolate Mofetil
  • Mycophenolate Sodium
  • Teriflunomide Tablets
  • Tofacitinib
  • Sirolimus
  • Other
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Chongqing Laimi Pharmaceutical Co., Ltd.
  • Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • Suzhou Changzheng-Xinkai Pharmaceutical Co., Ltd.
  • Shijiazhuang Huaxin Pharmaceutical Co., Ltd.
  • Xiamen Lizhuo Pharmaceutical Co., Ltd.
  • Qilu Pharmaceutical Co., Ltd.
  • Merro Pharmaceutical Co., Ltd.
  • Jiangsu Yabang Epson Pharmaceutical Co., Ltd.
  • Jichuang Pharmaceutical Group Co., Ltd.
  • North China Pharmaceutical Co., Ltd.
  • Hunan Warner Pharmaceutical Co., Ltd.
  • Hubei Tianyi Pharmaceutical Co., Ltd.
  • Fujian Huitian Biopharmaceutical Co., Ltd.
  • Chenxin Pharmaceutical Co., Ltd.
  • Changzhou Watson Pharmaceutical Co., Ltd.
  • Beijing Shuanglu Pharmaceutical Co., Ltd.
  • Teva
  • Sanofi
  • Pfizer
  • Manus Aktteva Biopharma LLP
  • Lupin Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals US
  • Alexion Pharmaceuticals, Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Selective Immunosuppressants Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Selective Immunosuppressants Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Selective Immunosuppressants Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Selective Immunosuppressants Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Selective Immunosuppressants Market Dynamics
  1. 2.1 Selective Immunosuppressants Industry Trends
  2. 2.2 Selective Immunosuppressants Industry Drivers
  3. 2.3 Selective Immunosuppressants Industry Opportunities and Challenges
  4. 2.4 Selective Immunosuppressants Industry Restraints
3 Selective Immunosuppressants Market by Manufacturers
  1. 3.1 Global Selective Immunosuppressants Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Selective Immunosuppressants Sales by Manufacturers (2021-2026)
  3. 3.3 Global Selective Immunosuppressants Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Selective Immunosuppressants Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Selective Immunosuppressants Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Selective Immunosuppressants Manufacturers, Product Type & Application
  7. 3.7 Global Selective Immunosuppressants Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Selective Immunosuppressants Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Selective Immunosuppressants Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Selective Immunosuppressants Tier 1, Tier 2, and Tier 3
4 Selective Immunosuppressants Market by Type
  1. 4.1 Selective Immunosuppressants Type Introduction
  2. 4.1.1 Leflunomide
  3. 4.1.2 Mycophenolate Mofetil
  4. 4.1.3 Mycophenolate Sodium
  5. 4.1.4 Teriflunomide Tablets
  6. 4.1.5 Tofacitinib
  7. 4.1.6 Sirolimus
  8. 4.1.7 Other
  9. 4.2 Global Selective Immunosuppressants Sales by Type
  10. 4.2.1 Global Selective Immunosuppressants Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Selective Immunosuppressants Sales by Type (2021-2032)
  12. 4.2.3 Global Selective Immunosuppressants Sales Market Share by Type (2021-2032)
  13. 4.3 Global Selective Immunosuppressants Revenue by Type
  14. 4.3.1 Global Selective Immunosuppressants Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Selective Immunosuppressants Revenue by Type (2021-2032)
  16. 4.3.3 Global Selective Immunosuppressants Revenue Market Share by Type (2021-2032)
5 Selective Immunosuppressants Market by Application
  1. 5.1 Selective Immunosuppressants Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Selective Immunosuppressants Sales by Application
  6. 5.2.1 Global Selective Immunosuppressants Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Selective Immunosuppressants Sales by Application (2021-2032)
  8. 5.2.3 Global Selective Immunosuppressants Sales Market Share by Application (2021-2032)
  9. 5.3 Global Selective Immunosuppressants Revenue by Application
  10. 5.3.1 Global Selective Immunosuppressants Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Selective Immunosuppressants Revenue by Application (2021-2032)
  12. 5.3.3 Global Selective Immunosuppressants Revenue Market Share by Application (2021-2032)
6 Global Selective Immunosuppressants Sales by Region
  1. 6.1 Global Selective Immunosuppressants Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Selective Immunosuppressants Sales by Region (2021-2032)
  3. 6.2.1 Global Selective Immunosuppressants Sales by Region (2021-2026)
  4. 6.2.2 Global Selective Immunosuppressants Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Selective Immunosuppressants Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Selective Immunosuppressants Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Selective Immunosuppressants Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Selective Immunosuppressants Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Selective Immunosuppressants Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Selective Immunosuppressants Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Selective Immunosuppressants Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Selective Immunosuppressants Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Selective Immunosuppressants Revenue by Region
  1. 7.1 Global Selective Immunosuppressants Revenue by Region
  2. 7.1.1 Global Selective Immunosuppressants Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Selective Immunosuppressants Revenue by Region (2021-2026)
  4. 7.1.3 Global Selective Immunosuppressants Revenue by Region (2027-2032)
  5. 7.1.4 Global Selective Immunosuppressants Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Selective Immunosuppressants Revenue (2021-2032)
  8. 7.2.2 North America Selective Immunosuppressants Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Selective Immunosuppressants Revenue (2021-2032)
  11. 7.3.2 Europe Selective Immunosuppressants Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Selective Immunosuppressants Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Selective Immunosuppressants Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Selective Immunosuppressants Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Selective Immunosuppressants Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Chongqing Laimi Pharmaceutical Co., Ltd.
  2. 8.1.1 Chongqing Laimi Pharmaceutical Co., Ltd. Company Information
  3. 8.1.2 Chongqing Laimi Pharmaceutical Co., Ltd. Business Overview
  4. 8.1.3 Chongqing Laimi Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chongqing Laimi Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio
  6. 8.1.5 Chongqing Laimi Pharmaceutical Co., Ltd. Recent Developments
  7. 8.2 Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd.
  8. 8.2.1 Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd. Company Information
  9. 8.2.2 Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd. Business Overview
  10. 8.2.3 Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio
  12. 8.2.5 Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd. Recent Developments
  13. 8.3 Zhejiang Hisun Pharmaceutical Co., Ltd.
  14. 8.3.1 Zhejiang Hisun Pharmaceutical Co., Ltd. Company Information
  15. 8.3.2 Zhejiang Hisun Pharmaceutical Co., Ltd. Business Overview
  16. 8.3.3 Zhejiang Hisun Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Zhejiang Hisun Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio
  18. 8.3.5 Zhejiang Hisun Pharmaceutical Co., Ltd. Recent Developments
  19. 8.4 Suzhou Changzheng-Xinkai Pharmaceutical Co., Ltd.
  20. 8.4.1 Suzhou Changzheng-Xinkai Pharmaceutical Co., Ltd. Company Information
  21. 8.4.2 Suzhou Changzheng-Xinkai Pharmaceutical Co., Ltd. Business Overview
  22. 8.4.3 Suzhou Changzheng-Xinkai Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Suzhou Changzheng-Xinkai Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio
  24. 8.4.5 Suzhou Changzheng-Xinkai Pharmaceutical Co., Ltd. Recent Developments
  25. 8.5 Shijiazhuang Huaxin Pharmaceutical Co., Ltd.
  26. 8.5.1 Shijiazhuang Huaxin Pharmaceutical Co., Ltd. Company Information
  27. 8.5.2 Shijiazhuang Huaxin Pharmaceutical Co., Ltd. Business Overview
  28. 8.5.3 Shijiazhuang Huaxin Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Shijiazhuang Huaxin Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio
  30. 8.5.5 Shijiazhuang Huaxin Pharmaceutical Co., Ltd. Recent Developments
  31. 8.6 Xiamen Lizhuo Pharmaceutical Co., Ltd.
  32. 8.6.1 Xiamen Lizhuo Pharmaceutical Co., Ltd. Company Information
  33. 8.6.2 Xiamen Lizhuo Pharmaceutical Co., Ltd. Business Overview
  34. 8.6.3 Xiamen Lizhuo Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Xiamen Lizhuo Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio
  36. 8.6.5 Xiamen Lizhuo Pharmaceutical Co., Ltd. Recent Developments
  37. 8.7 Qilu Pharmaceutical Co., Ltd.
  38. 8.7.1 Qilu Pharmaceutical Co., Ltd. Company Information
  39. 8.7.2 Qilu Pharmaceutical Co., Ltd. Business Overview
  40. 8.7.3 Qilu Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Qilu Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio
  42. 8.7.5 Qilu Pharmaceutical Co., Ltd. Recent Developments
  43. 8.8 Merro Pharmaceutical Co., Ltd.
  44. 8.8.1 Merro Pharmaceutical Co., Ltd. Company Information
  45. 8.8.2 Merro Pharmaceutical Co., Ltd. Business Overview
  46. 8.8.3 Merro Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Merro Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio
  48. 8.8.5 Merro Pharmaceutical Co., Ltd. Recent Developments
  49. 8.9 Jiangsu Yabang Epson Pharmaceutical Co., Ltd.
  50. 8.9.1 Jiangsu Yabang Epson Pharmaceutical Co., Ltd. Company Information
  51. 8.9.2 Jiangsu Yabang Epson Pharmaceutical Co., Ltd. Business Overview
  52. 8.9.3 Jiangsu Yabang Epson Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Yabang Epson Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio
  54. 8.9.5 Jiangsu Yabang Epson Pharmaceutical Co., Ltd. Recent Developments
  55. 8.10 Jichuang Pharmaceutical Group Co., Ltd.
  56. 8.10.1 Jichuang Pharmaceutical Group Co., Ltd. Company Information
  57. 8.10.2 Jichuang Pharmaceutical Group Co., Ltd. Business Overview
  58. 8.10.3 Jichuang Pharmaceutical Group Co., Ltd. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Jichuang Pharmaceutical Group Co., Ltd. Selective Immunosuppressants Product Portfolio
  60. 8.10.5 Jichuang Pharmaceutical Group Co., Ltd. Recent Developments
  61. 8.11 North China Pharmaceutical Co., Ltd.
  62. 8.11.1 North China Pharmaceutical Co., Ltd. Company Information
  63. 8.11.2 North China Pharmaceutical Co., Ltd. Business Overview
  64. 8.11.3 North China Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 North China Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio
  66. 8.11.5 North China Pharmaceutical Co., Ltd. Recent Developments
  67. 8.12 Hunan Warner Pharmaceutical Co., Ltd.
  68. 8.12.1 Hunan Warner Pharmaceutical Co., Ltd. Company Information
  69. 8.12.2 Hunan Warner Pharmaceutical Co., Ltd. Business Overview
  70. 8.12.3 Hunan Warner Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Hunan Warner Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio
  72. 8.12.5 Hunan Warner Pharmaceutical Co., Ltd. Recent Developments
  73. 8.13 Hubei Tianyi Pharmaceutical Co., Ltd.
  74. 8.13.1 Hubei Tianyi Pharmaceutical Co., Ltd. Company Information
  75. 8.13.2 Hubei Tianyi Pharmaceutical Co., Ltd. Business Overview
  76. 8.13.3 Hubei Tianyi Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Hubei Tianyi Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio
  78. 8.13.5 Hubei Tianyi Pharmaceutical Co., Ltd. Recent Developments
  79. 8.14 Fujian Huitian Biopharmaceutical Co., Ltd.
  80. 8.14.1 Fujian Huitian Biopharmaceutical Co., Ltd. Company Information
  81. 8.14.2 Fujian Huitian Biopharmaceutical Co., Ltd. Business Overview
  82. 8.14.3 Fujian Huitian Biopharmaceutical Co., Ltd. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Fujian Huitian Biopharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio
  84. 8.14.5 Fujian Huitian Biopharmaceutical Co., Ltd. Recent Developments
  85. 8.15 Chenxin Pharmaceutical Co., Ltd.
  86. 8.15.1 Chenxin Pharmaceutical Co., Ltd. Company Information
  87. 8.15.2 Chenxin Pharmaceutical Co., Ltd. Business Overview
  88. 8.15.3 Chenxin Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Chenxin Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio
  90. 8.15.5 Chenxin Pharmaceutical Co., Ltd. Recent Developments
  91. 8.16 Changzhou Watson Pharmaceutical Co., Ltd.
  92. 8.16.1 Changzhou Watson Pharmaceutical Co., Ltd. Company Information
  93. 8.16.2 Changzhou Watson Pharmaceutical Co., Ltd. Business Overview
  94. 8.16.3 Changzhou Watson Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Changzhou Watson Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio
  96. 8.16.5 Changzhou Watson Pharmaceutical Co., Ltd. Recent Developments
  97. 8.17 Beijing Shuanglu Pharmaceutical Co., Ltd.
  98. 8.17.1 Beijing Shuanglu Pharmaceutical Co., Ltd. Company Information
  99. 8.17.2 Beijing Shuanglu Pharmaceutical Co., Ltd. Business Overview
  100. 8.17.3 Beijing Shuanglu Pharmaceutical Co., Ltd. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Beijing Shuanglu Pharmaceutical Co., Ltd. Selective Immunosuppressants Product Portfolio
  102. 8.17.5 Beijing Shuanglu Pharmaceutical Co., Ltd. Recent Developments
  103. 8.18 Teva
  104. 8.18.1 Teva Company Information
  105. 8.18.2 Teva Business Overview
  106. 8.18.3 Teva Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Teva Selective Immunosuppressants Product Portfolio
  108. 8.18.5 Teva Recent Developments
  109. 8.19 Sanofi
  110. 8.19.1 Sanofi Company Information
  111. 8.19.2 Sanofi Business Overview
  112. 8.19.3 Sanofi Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Sanofi Selective Immunosuppressants Product Portfolio
  114. 8.19.5 Sanofi Recent Developments
  115. 8.20 Pfizer
  116. 8.20.1 Pfizer Company Information
  117. 8.20.2 Pfizer Business Overview
  118. 8.20.3 Pfizer Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Pfizer Selective Immunosuppressants Product Portfolio
  120. 8.20.5 Pfizer Recent Developments
  121. 8.21 Manus Aktteva Biopharma LLP
  122. 8.21.1 Manus Aktteva Biopharma LLP Company Information
  123. 8.21.2 Manus Aktteva Biopharma LLP Business Overview
  124. 8.21.3 Manus Aktteva Biopharma LLP Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Manus Aktteva Biopharma LLP Selective Immunosuppressants Product Portfolio
  126. 8.21.5 Manus Aktteva Biopharma LLP Recent Developments
  127. 8.22 Lupin Pharmaceuticals, Inc.
  128. 8.22.1 Lupin Pharmaceuticals, Inc. Company Information
  129. 8.22.2 Lupin Pharmaceuticals, Inc. Business Overview
  130. 8.22.3 Lupin Pharmaceuticals, Inc. Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Lupin Pharmaceuticals, Inc. Selective Immunosuppressants Product Portfolio
  132. 8.22.5 Lupin Pharmaceuticals, Inc. Recent Developments
  133. 8.23 Glenmark Pharmaceuticals US
  134. 8.23.1 Glenmark Pharmaceuticals US Company Information
  135. 8.23.2 Glenmark Pharmaceuticals US Business Overview
  136. 8.23.3 Glenmark Pharmaceuticals US Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Glenmark Pharmaceuticals US Selective Immunosuppressants Product Portfolio
  138. 8.23.5 Glenmark Pharmaceuticals US Recent Developments
  139. 8.24 Alexion Pharmaceuticals, Inc
  140. 8.24.1 Alexion Pharmaceuticals, Inc Company Information
  141. 8.24.2 Alexion Pharmaceuticals, Inc Business Overview
  142. 8.24.3 Alexion Pharmaceuticals, Inc Selective Immunosuppressants Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Alexion Pharmaceuticals, Inc Selective Immunosuppressants Product Portfolio
  144. 8.24.5 Alexion Pharmaceuticals, Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Selective Immunosuppressants Value Chain Analysis
  2. 9.1.1 Selective Immunosuppressants Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Selective Immunosuppressants Production Mode & Process
  6. 9.2 Selective Immunosuppressants Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Selective Immunosuppressants Distributors
  9. 9.2.3 Selective Immunosuppressants Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst